MedPath

Eye Patch Therapy for Central Serous Retinopathy (CSR)

Phase 1
Completed
Conditions
Central Serous Retinopathy (CSR)
Interventions
Device: Eye Patching
Registration Number
NCT02036632
Lead Sponsor
Washington University School of Medicine
Brief Summary

First, this study will investigate the viability of 24-hour eye patching as a potential treatment modality for CSR. Second, this study will assess a potential physiologic explanation for CSR, namely if inhibition of photic stimulation of the diseased retina will aid in ameliorating disease severity and disease duration.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
12
Inclusion Criteria
  • Adults 18 years of age and older
  • Both males and females
  • Patients diagnosed with active central serous retinopathy
  • Patients who are willing to use an eye patch in the affected eye for 24 hours
  • Patients who are able to make the follow up appointments as required by the study
Read More
Exclusion Criteria
  • Individuals under 18 years of age
  • Patients with vision less than 20/40 in the unaffected eye.
  • Patients who are not able to undergo mfERG testing in a realiable manner.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Eye PatchingEye PatchingIntervention
Primary Outcome Measures
NameTimeMethod
Change in multi-focal ERG response24 hours
Change in multi-focal ERG response and macular thickness after 24-hour patch therapy in patients with CSR24 hours

This study is a prospective control trial that will compare 24-hour eye patch therapy with the current standard of care in patients with central serous retinopathy (CSR).

Secondary Outcome Measures
NameTimeMethod
macular thickness24 hours

Trial Locations

Locations (1)

Washington Universtiy School of Medicine

🇺🇸

St Louis, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath